Search

Your search keyword '"Insomnia -- Drug therapy"' showing total 599 results
Start Over Descriptor "Insomnia -- Drug therapy"
599 results on '"Insomnia -- Drug therapy"'

1. Data from Dong-eui University College of Korean Medicine Provide New Insights into Menopause (Effectiveness and safety of East Asian herbal medicine for menopausal insomnia: a systematic review and meta-analysis)

Subjects
Women -- Health aspects, Safety regulations -- Analysis, Insomnia -- Drug therapy, Menopause -- Drug therapy, Medicine, Botanic -- Analysis, Medicine, Herbal -- Analysis, Health, Women's issues/gender studies
Abstract

2024 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in menopause. According to news originating from Busan, South Korea, [...]

Published
2024

2. Research on Sleep Disorders Reported by Researchers at Uttaranchal University (Sleep Disorder and its Treatment: From Nature to Laboratory)

Subjects
Medical research, Medicine, Experimental, Movement disorders -- Drug therapy, Insomnia -- Drug therapy, Ropinirole, Pramipexole, Narcolepsy -- Drug therapy, Sleep apnea syndromes -- Drug therapy, Physical fitness, Health
Abstract

2024 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in sleep disorders. According to news originating from [...]

Published
2024

3. Seltorexant Improves Both Depressive and Insomnia Symptoms in MDD Patients

Author

Ernst, Diana

Subjects
Insomnia -- Drug therapy, Depression, Mental -- Drug therapy, Health
Abstract

Seltorexant, an investigational selective orexin-2 receptor antagonist, was associated with statistically significant and clinically meaningful antidepressant effects in adults with major depressive disorder (MDD) with insomnia symptoms, according to results [...]

Published
2024

4. Sleep Disorder Treatment Market Is Projected to Grow at a CAGR of 7.84%, Reaching USD 40.0 Billion by 2032

Subjects
Insomnia -- Drug therapy, Patient compliance -- Statistics -- Forecasts and trends, Sleep apnea syndromes -- Drug therapy, Eszopiclone -- Statistics, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

Pune: SNS Insider pvt ltd has issued the following news release: The S&S Insider report indicates that, 'The sleep disorder treatment market was valued at USD 20.3 billion in 2023 [...]

Published
2024

5. Study Findings on Neurology Described by Researchers at University of Bristol School of Medicine (Assessing insomnia after stroke: a diagnostic validation of the Sleep Condition Indicator in self-reported stroke survivors)

Subjects
Stroke (Disease) -- Drug therapy, Insomnia -- Drug therapy, Stroke patients -- Analysis
Abstract

2024 NOV 22 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in neurology. According to news reporting out of Bristol, [...]

Published
2024

6. U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs

Subjects
Continuous positive airway pressure -- Forecasts and trends, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep Studies & CPAPs' report from Marketdata LLC has been added to [...]

Published
2024

7. U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs - ResearchAndMarkets.com

Subjects
Continuous positive airway pressure -- Forecasts and trends, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, Market trend/market analysis, Business, Business, international
Abstract

DUBLIN -- The 'U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep Studies & CPAPs' report from Marketdata LLC has been added to ResearchAndMarkets.com's offering. 70% of Americans are estimated to [...]

Published
2024

8. U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs

Subjects
Continuous positive airway pressure -- Forecasts and trends, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-September 4, 2024-: U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs (C)1994-2024 M2 COMMUNICATIONS RDATE:04092024 The 'U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep [...]

Published
2024

9. U.S. Food and Drug Administration Grants Clearance for Big Health's SleepioRx

Subjects
United States. Food and Drug Administration, Insomnia -- Drug therapy, Cognitive therapy -- Health aspects, Health care industry -- Health aspects, Health care industry, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Big Health has issued the following news release: Big Health, the leading developer of digital treatments for the most common mental health conditions, has been granted clearance by [...]

Published
2024

11. Antidepressants Help with Physical and Emotional Challenges of Aging: Hot flashes, anxiety, and insomnia are among the many health issues managed with these medications

Subjects
Insomnia -- Drug therapy, Antidepressants, Tricyclic -- Health aspects, Depression, Mental -- Drug therapy, Menopause -- Drug therapy, Health
Abstract

About 25 percent of women ages 60 and older are treated with antidepressants, while just half that number of men take this type of medication. But the term 'antidepressants can [...]

Published
2024

12. Benzodiazepine and Z-hypnotic stewardship

Author

Wright, Steven

Subjects
Insomnia -- Drug therapy, Benzodiazepines -- Complications and side effects -- Patient outcomes, Anxiety -- Drug therapy, Health
Abstract

These agents are not first-line treatments for many of the conditions for which they are used. When they are used, there should be a plan in place for deprescribing. Benzodiazepines [...]

Published
2022
Full Text
View/download PDF

13. Research and Markets Offers Report: Insomnia Drugs Business Research 2023-2030

Subjects
Insomnia -- Drug therapy, Hypnotics -- Market research, Sedatives -- Market research, Pharmaceutical industry -- Market research, Marketing research, Business, Business, international, Telecommunications industry
Abstract

The 'Insomnia Drugs - Global Strategic Business Report' report has been added to ResearchAndMarkets.com's offering. According to a release, the global market for Insomnia Drugs was estimated at US$3.9 Billion [...]

Published
2024

14. Data on Cancer Reported by Le-le Zhang and Colleagues (Rules of acupoint selection in treatment of cancer-related insomnia with acupuncture and moxibustion based on data mining technology)

Subjects
Insomnia -- Drug therapy, Cancer -- Drug therapy, Data mining, Acupuncture, Data warehousing/data mining, Computers
Abstract

2024 JUL 30 (VerticalNews) -- By a News Reporter-Staff News Editor at Information Technology Newsweekly -- New research on Cancer is the subject of a report. According to news originating [...]

Published
2024

16. Insomnia Drugs Market Set to Reach USD 4.30 Billion by 2030, Driven by Advancements in Sleep Disorder Treatments

Subjects
Options (Finance) -- Forecasts and trends -- Reports, Insomnia -- Drug therapy, Drugs -- Forecasts and trends -- Reports, Pharmacy -- Forecasts and trends -- Reports, Antiparkinsonian agents -- Forecasts and trends -- Reports, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: RESEARCH AND MARKETS has issued the following news release: The 'Global Insomnia Drugs Market by Type (Anti-Parkinsonian Drugs, Anticonvulsants, Antidepressants), Distribution Channels (Online Pharmacies, Retail Pharmacies) - Forecast 2024-2030' [...]

Published
2024

17. Studies from Eisai Co. Ltd. Add New Findings in the Area of Sleep Disorders (Efficacy of Lemborexant In Adults 65 Years of Age With Insomnia Disorder)

Subjects
Eisai Company Ltd. -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Aged -- Reports, Insomnia -- Drug therapy, Mental health -- Reports, Pharmaceutical industry -- Reports, Health, Psychology and mental health
Abstract

2024 JUN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Fresh data on Sleep Diseases and Conditions - Sleep Disorders are presented in [...]

Published
2024

19. Report Summarizes Nanoemulsions Study Findings from Department of Pharmaceutical (Essential Oils Enriched Self-nano-emulsifying Systems for Effective Oral Delivery of Zaleplon for Improvement of Insomnia Treatment)

Subjects
Drugs -- Vehicles, Insomnia -- Drug therapy, Zaleplon -- Dosage and administration, Drug delivery systems -- Testing, Bioavailability -- Testing, Health
Abstract

2022 NOV 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Nanotechnology - Nanoemulsions. According to news reporting [...]

Published
2022

20. Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia

Subjects
Mochida Pharmaceutical Company Ltd., Insomnia -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

Tokyo, Japan and Cambridge: Sosei Group Corporation has issued the following news release: Sosei Group Corporation ('Sosei Heptares' or 'the Company'; TSE: 4565) announces that Idorsia Pharmaceuticals Japan Ltd. ('Idorsia [...]

Published
2023

21. Insomnia treatment market faces need for innovation as Z-drugs show limitations, says GlobalData. [1 table in original article]

Subjects
Taisho Pharmaceutical Company Ltd. -- Innovations, Insomnia -- Drug therapy, Ramelteon -- Comparative analysis, Generic drugs -- Innovations, Antihistamines -- Innovations, Drug approval -- Comparative analysis, Pharmaceutical industry -- Comparative analysis -- Innovations, Business, Chemicals, plastics and rubber industries
Abstract

Benzodiazepine-like Z-drugs have dominated the insomnia pharmacological treatment market for the past 30 years. However, due to their unfavourable side effect profile, there is a need for additional treatment options. There are currently four Phase III products in development for the treatment of insomnia. However, they do not possess novel mechanisms of action (MOA) that differentiate them from marketed products, says GlobalData, a leading data and analytics company. The approval of dual orexin receptor antagonists (DORAs) for the treatment of insomnia, which selectively inhibit arousal and promote sleep, offer a superior safety profile when compared to Z-drugs. Unfortunately, there is a limited number of late-stage pipeline agents for insomnia, with only four products in Phase III development: Vanda Pharmaceuticals' Hetlioz (tasimelteon), EUSOL Biotech's SM-1 (diphenhydramine + lorazepam + zolpidem), Taisho Pharmaceutical's vornorexant, and Johnson and Johnson's (J&J) seltorexant. Hetlioz is a melatonin agonist that is already FDA approved for two rare sleep disorders: non-24-hour sleep wake disorder and Smith-Magenis syndrome. But Vanda Pharmaceuticals is looking to pursue label expansion, with plans to file an sNDA for the treatment of insomnia in 2024. This would set up the drug to compete with marketed melatonin receptor agonists including Takeda's Rozerem (ramelteon) and generic versions of ramelteon. SM-1 combines an antihistamine (diphenhydramine), benzodiazepine (lorazepam), and a Z-drug (zolpidem) in a single pill for the treatment of acute insomnia. However, inexpensive generic versions of each of these drugs are already marketed separately for insomnia, which could limit the uptake of the combined formulation. Taisho's vornorexant could be the next DORA to enter the market and compete with Merck's Belsomra (suvorexant), Eisai's Dayvigo (lemborexant), and Idorsia's Quviviq (daridorexant). Unlike DORAs, which target both orexin receptor type 1 and type 2, J&J's seltorexant selectively antagonizes orexin receptor type 2 and is being investigated as an adjunctive therapy to antidepressants for patients with major depressive disorder and insomnia symptoms. A table presents an overview of the insomnia pipeline in the 7MM. Original source: Global Data, website: http://www.energy.globaldata.com, Copyright Global Data 2023., market; regulations and rulings; research and development; Belsomra; benzodiazepine; daridorexant; Dayvigo; diphenhydramine; generic pharmaceuticals; Hetlioz; lemborexant; lorazepam; Quviviq; ramelteon; ramelteon; seltorexant; sleep disorder treatments; suvorexant; tasimelteon; vornorexant; zolpidem; Eisai; EUSOL [...]

Published
2023

22. Lemborexant at least as effective as other hypnotics for insomnia

Subjects
Insomnia -- Drug therapy, Clinical psychiatry -- Analysis, Pharmaceuticals and cosmetics industries, Health, Psychology and mental health
Abstract

* Researchers conducted 'number needed to treat' and 'number needed to harm' analyses to evaluate the effectiveness of lemborexant for the treatment of adults with insomnia. * Results suggested that lemborexant has a clinically meaningful effect relative to placebo and is relatively tolerable, with a stronger effect size than zolpidem extended-release relative to placebo. * The 5-mg dose of lemborexant was better tolerated than the 10-mg dose., The dual orexin receptor antagonist (DORA) lemborexant is at least as effective as other hypnotics for the treatment of adults with insomnia, an analysis of data from two Phase 3 [...]

Published
2021

23. Electroacupuncture May Aid Depression-Related Insomnia

Subjects
Insomnia -- Drug therapy, Acupuncture -- Reports, Health
Abstract

HealthDay News — Electroacupuncture (EA) treatment is safe and effective for insomnia in patients with depression, according to a study published online July 7 in JAMA Network Open. Xuan Yin, [...]

Published
2022

24. Sleep Disorder Treatment Market is to Hit USD 18 Billion by 2030 Rising demand due to the Increasing Stress and Lifestyle-Related Disorders | Research by SNS Insider

Subjects
Medical research, Medicine, Experimental, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, General interest, News, opinion and commentary
Abstract

Pune: 'The Sleep Disorder Treatment Market size was escalated at USD 9.2 billion in 2022 and is projected to reach USD 18 billion by 2030 with growing healthy CAGR of [...]

Published
2023

25. Advanced Hypnotherapy of Naples Launches Innovative Solutions for Insomnia, Florida Weight Loss Center, and PTSD Treatment Clinic near Me

Subjects
Hypnotism -- Drug therapy, Insomnia -- Drug therapy, Evidence-based medicine, Weight loss -- Drug therapy, General interest
Abstract

New Delhi, July 18 -- Insomnia, a sleep disorder affecting millions worldwide, can have a significant impact on daily life and overall well-being. Advanced Hypnotherapy of Naples has developed a [...]

Published
2023

26. Oomph Body's Natural Sleep Aids Beat Pharmaceutical Alternatives

Subjects
Insomnia -- Drug therapy, Sleep deprivation -- Drug therapy, General interest, News, opinion and commentary
Abstract

FORT LAUDERDALE: Oomph Body has issued the following news release: Insomnia is a common struggle. As much as 33% of adults struggle with significant sleep deprivation, while one in 10 [...]

Published
2023

27. Reports from McGill University Provide New Insights into Personality Disorders (Sleep Quality After Quetiapine Augmentation In Patients With Treatment-resistant Depression and Personality Disorders)

Subjects
Insomnia -- Drug therapy, Quetiapine -- Reports, Mental health -- Reports, Personality disorders -- Drug therapy, Depression, Mental -- Drug therapy, Health, Psychology and mental health, McGill University -- Reports
Abstract

2023 DEC 18 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Fresh data on Mental Health Diseases and Conditions - Personality Disorders are presented [...]

Published
2023

28. Virginia Polytechnic Institute and State University (Virginia Tech) Researcher Details Findings in Anxiety Disorders (Efficacy of Cognitive Behavioral Therapy for Insomnia for the Treatment of Child and Adolescent Anxiety and Depression)

Subjects
Insomnia -- Drug therapy, Cognitive therapy -- Psychological aspects -- Reports, Technical institutes -- Evaluation, Child psychopathology -- Drug therapy, Behavioral health care -- Psychological aspects -- Reports, Anxiety -- Drug therapy, Health, Virginia Polytechnic Institute and State University -- Evaluation -- Reports
Abstract

2023 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on anxiety disorders is the subject of a new report. According [...]

Published
2023

29. Suvorexant May Aid Insomnia Tied to Hot Flashes

Subjects
Insomnia -- Drug therapy, Postmenopausal women -- Drug therapy, Menopause -- Drug therapy, Health
Abstract

HealthDay News — Suvorexant may aid insomnia associated with hot flashes in perimenopausal and postmenopausal women, according to a study recently published in SLEEP. Shadab A. Rahman, PhD, from Brigham [...]

Published
2022

30. Quviviq Approved for the Treatment of Insomnia

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Insomnia -- Drug therapy, Drug approval, Health
Abstract

The Food and Drug Administration (FDA) has approved Quviviq™ (daridorexant) for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Daridorexant is a dual [...]

Published
2022

31. New Anxiolytics Sedatives and Hypnotics Data Have Been Reported by Researchers at University of Jinan (Efficacy and Safety of Zolpidem In the Treatment of Insomnia Disorder for One Month: a Meta-analysis of a Randomized Controlled Trial)

Subjects
Zolpidem -- Analysis, Insomnia -- Drug therapy, Antianxiety agents -- Analysis, Physical fitness -- Analysis, Health
Abstract

2021 DEC 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Anxiolytics Sedatives and Hypnotics [...]

Published
2021

32. Investigators at College of Science Detail Findings in Anxiolytics Sedatives and Hypnotics (Novel Solid Forms of Insomnia Drug Suvorexant With Improved Solubility and Dissolution: Accessing Salts From a Salt Solvate Route)

Subjects
Insomnia -- Drug therapy, Antianxiety agents, Physical fitness, Health
Abstract

2021 NOV 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - Anxiolytics Sedatives and [...]

Published
2021

33. Data on Alzheimer Disease Described by Researchers at University of California Los Angeles (UCLA) (Impact of Pharmacotherapy On Insomnia In Patients With Alzheimer's Disease)

Subjects
Medical research, Medicine, Experimental, Insomnia -- Drug therapy, Alzheimer's disease -- Drug therapy, Physical fitness, Health
Abstract

2021 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Neurodegenerative Diseases and Conditions - Alzheimer Disease have been [...]

Published
2021

34. Eisai introduces anti-insomnia drug, Dayvigo to treat insomnia in Hong Kong

Subjects
Insomnia -- Drug therapy, Pharmaceuticals and cosmetics industries, Dayvigo (Medication)
Abstract

Eisai announced that its Hong Kong subsidiary Eisai (Hong Kong) has launched the in-house-discovered and developed orexin receptor antagonist Dayvigo (generic name: lemborexant) for the treatment of adults with insomnia, [...]

Published
2021

35. Sleep Disorders Treatment Global Market Report 2023: Growing Demand for Home Sleep Tests Presents Opportunities

Subjects
Insomnia -- Drug therapy, Mental health -- Forecasts and trends -- Statistics, Marketing research, Market trend/market analysis, Business, News, opinion and commentary
Abstract

DUBLIN, March 31, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5755902/sleep-disorders-treatment-global-market-outlook?utm_source=CI&utm_medium=PressRelease&utm_code=nxs6z2&utm_campaign=1835932+-+Sleep+Disorders+Treatment+Global+Market+Report+2023%3a+Growing+Demand+for+Home+Sleep+Tests+Presents+Opportunities&utm_exec=como322prd report has been added toResearchAndMarkets.com's offering. In this report, the market has been segmented based on product type, medication type, and geography. [...]

Published
2023

36. What an Expert Says About Taking Magnesium for Sleep

Author

Murez, Cara

Subjects
Insomnia -- Drug therapy, Hypnotics -- Dosage and administration, Sleep therapy -- Patient outcomes, Sedatives -- Dosage and administration, Magnesium in the body -- Dosage and administration, Health
Abstract

Byline: Cara Murez HealthDay Reporter WEDNESDAY, March 8, 2023 (HealthDay News) -- When people struggle to fall asleep, itâ[euro](tm)s no surprise they seek solutions. Options can range from prescription medications [...]

Published
2023

37. New Anxiety Disorders Data Have Been Reported by Investigators at Boston Children's Hospital (Efficacy of Cognitive Behavioral Therapy for Insomnia for the Treatment of Child and Adolescent Anxiety and Depression a Systematic Review From ...)

Subjects
Insomnia -- Drug therapy, Cognitive therapy -- Psychological aspects -- Reports, Mental health -- Psychological aspects -- Reports, Child psychopathology -- Drug therapy, Behavioral health care -- Psychological aspects -- Reports, Anxiety -- Drug therapy, Health, Children's Hospital (Boston, Massachusetts) -- Evaluation -- Reports
Abstract

2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Mental Health Diseases and Conditions - Anxiety Disorders is the [...]

Published
2023

38. Eisai's anti-insomnia drug, Dayvigo gets approval in Hong Kong

Subjects
Eisai (Hong Kong) Company Ltd., Eisai Company Ltd., Insomnia -- Drug therapy, Drug approval, Pharmaceutical industry, Pharmaceuticals and cosmetics industries, Dayvigo (Medication)
Abstract

Eisai Co, Ltd announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) for the treatment [...]

Published
2021

39. You might be using melatonin all wrong. Here's what you should know

Author

Chiu, Allyson

Subjects
Sleep-wake cycle -- Management, Insomnia -- Drug therapy, Melatonin -- Usage -- Health aspects, Company business management, General interest, News, opinion and commentary
Abstract

Byline: Allyson Chiu By the time sleep-starved people come to Jennifer Martin, a psychologist who specializes in insomnia, many have already 'tried everything they can possibly buy over-the-counter,' she said. [...]

Published
2022

40. Investigators at University of Western Ontario Zero in on Obstructive Sleep Apnea (Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System)

Subjects
United States. Food and Drug Administration, Physical fitness, Finasteride, Respiratory tract diseases -- Drug therapy, Insomnia -- Drug therapy, Sexual disorders -- Drug therapy, Sleep apnea -- Drug therapy, Health, University of Western Ontario
Abstract

2020 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Respiratory Tract Diseases and Conditions - Obstructive [...]

Published
2020

41. Hong Kong Department of Health accepts Eisai's NDA for new anti-insomnia drug, Dayvigo

Subjects
Eisai Company Ltd. -- Product development -- Planning, Insomnia -- Drug therapy, Pharmaceutical industry -- Product development -- Planning, Drug approval, Company business planning, Pharmaceuticals and cosmetics industries, Dayvigo (Medication) -- Product development
Abstract

Eisai Co., Ltd. announced that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) for the treatment of adults with insomnia, characterized by [...]

Published
2020

42. New study evaluates pharmacological treatment for insomnia

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Insomnia -- Drug therapy, Eszopiclone -- Reports, Business, international, University of Oxford -- Reports
Abstract

London: University of Oxford has issued the following news release: Two drugs, eszopiclone and lemborexant - both not currently licenced for the treatment of insomnia in the UK - were [...]

Published
2022

43. NEW STUDY EVALUATES PHARMACOLOGICAL TREATMENT FOR INSOMNIA

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Insomnia -- Drug therapy, Eszopiclone -- Reports, News, opinion and commentary, University of Oxford -- Reports
Abstract

OXFORD, UK -- The following information was released by the University of Oxford: Two drugs, eszopiclone and lemborexant -- both not currently licenced for the treatment of insomnia in the [...]

Published
2022

44. Two drugs show best efficacy, but concerns remain

Author

Brooks, Megan

Subjects
Insomnia -- Drug therapy, Hypnotics, Drugs, Sedatives, Health, Health care industry
Abstract

Two drugs have emerged as the optimal medications for treating insomnia based on the 'best-available evidence,' but there are caveats. In a comprehensive comparative-effectiveness analysis, lemborexant and eszopiclone showed the [...]

Published
2022

45. Daridorexant Receives Approval for Insomnia Treatment: Daridorexant demonstrated significant reduction in daytime sleepiness among other measures

Author

Tran, Tiana and Walton, Roy

Subjects
Insomnia -- Drug therapy, Drug approval -- Methods, Clinical trials -- Methods, Business, Pharmaceuticals and cosmetics industries
Abstract

On January 7, 2022, the FDA approved daridorexant (Quviviq) for the treatment of adults with insomnia.1 The approval was based on findings from a phase 3 clinical trial program in [...]

Published
2022

47. Eisai's Dayvigo receives US FDA approval to treat insomnia in adult

Subjects
United States. Food and Drug Administration, Eisai Company Ltd., Insomnia -- Drug therapy, Pharmaceutical industry, Drug approval, Adults, Narcotics control, Pharmaceuticals and cosmetics industries
Abstract

Eisai Co, Ltd announced that the US Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist Dayvigo (lemborexant). Dayvigo was [...]

Published
2019

49. University of Kentucky College of Medicine Researchers Further Understanding of Anxiety Disorders (Reductions in anxiety, depression and insomnia in health care workers using a non-pharmaceutical intervention)

Subjects
Workers, Insomnia -- Drug therapy, Anxiety -- Drug therapy, Medical personnel, Health
Abstract

2022 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators discuss new findings in anxiety disorders. According to news reporting originating from Lexington, [...]

Published
2022

50. Swell in off-label antipsychotic prescribing 'not harmless'

Author

Yasgur, Batya Swift

Subjects
Off-label prescribing -- Forecasts and trends -- Complications and side effects, Insomnia -- Drug therapy, Antipsychotic drugs -- Dosage and administration -- Complications and side effects, Cardiovascular diseases -- Risk factors -- Patient outcomes, Anxiety -- Drug therapy, Market trend/market analysis, Health, Health care industry, Psychology and mental health
Abstract

FROM THE JOURNAL OF PSYCHIATRIC RESEARCH A growing trend of off-label, low-dose antipsychotic prescribing to treat disorders such as anxiety and insomnia has been tied to an increased risk of [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results